A. Mysnyk

Problems of drug therapy for benign prostatic hyperplasia in Ukraine

The publication presents data on the possibilities of medical treatment of Benign Prostatic Hyperplasia (BPH). Particular attention is paid to issues in the process of studying: optimal duration of .-blockers and 5-.-reductase inhibitors therapy, ability to discontinuation .-blockers or 5-.-P-inhibitors from combination, potential risks of long-term 5­.-P inhibitors use. Emphasizes the relevance of optimizing the treatment of BPH due to the incessant incidence increase in Ukraine, which is associated with unfavorable demographic situation.